Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06487221 · ClinicalTrials.gov registry record · Phase 2
Avutometinib and Defactinib in Diffuse Gastric Cancer
A Phase 2 study of Gastric Cancer and Stomach Cancer, sponsored by Ryan H. Moy, MD, PhD.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 27
- Enrollment target
- 1
- Study location
NCT06487221 is a Phase 2 study of Gastric Cancer and Stomach Cancer that is actively recruiting participants, run by Ryan H. Moy, MD, PhD. The registered enrollment target is 27 participants, below the 319-participant average among 153 other Gastric Cancer trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06487221, a Phase 2 study of Gastric Cancer and Stomach Cancer, is actively recruiting participants, sponsored by Ryan H. Moy, MD, PhD.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 27 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine if the combination study treatment with avutometinib and defactinib will prolong life in participants, is effective in decreasing the size of the tumor(s), and if it is safe in subjects with diffuse-type stomach cancer.
Conditions Studied
Interventions
- DRUG Avutometinib
- DRUG Defactinib
Study Locations (1)
New York
- Columbia University Irving Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2024-10-28 |
| Est. Completion | 2029-05-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06487221
The ClinicalTrials.gov registry entry for NCT06487221 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 319-participant average among 153 other Gastric Cancer trials with a reported enrollment target (92% lower). The listed sponsor is Ryan H. Moy, MD, PhD, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Gastric Cancer appearing as the primary indexed condition, and to 2 interventions - of which Avutometinib is the first listed.
NCT06487221 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT06487221 about?
NCT06487221 is a clinical study titled "Avutometinib and Defactinib in Diffuse Gastric Cancer". The purpose of this study is to determine if the combination study treatment with avutometinib and defactinib will prolong life in participants, is effective in decreasing the size of the tumor(s), and if it is safe in subjects with diffuse-type stomach cancer.
What is the current status of trial NCT06487221?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 2024-10-28. Estimated completion is 2029-05-30.
What conditions does trial NCT06487221 study?
This clinical trial studies the following conditions: Gastric Cancer, Stomach Cancer.
What interventions are being tested in trial NCT06487221?
The interventions under investigation include: Avutometinib (DRUG), Defactinib (DRUG).
Who is sponsoring clinical trial NCT06487221?
This trial is sponsored by Ryan H. Moy, MD, PhD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06487221 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastric Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
RECRUITING · Phase 2
-
Combination of TATE and PD-1 Inhibitor in Liver Cancer
RECRUITING · Phase 2
-
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
RECRUITING · Phase 2
-
Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)
RECRUITING · Phase 2
-
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RECRUITING · Phase 2
-
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.